HLA Class I Heavy Chain antibody

Catalog No. ABIN5691100

Product Details

Target: HLA Class I Heavy Chain

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: ELISA, Western Blotting (WB), Flow Cytometry (FACS), Immunoprecipitation (IP), Electron Microscopy (EM), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Specificity: The mouse monoclonal antibody HC10 recognizes HLA class I heavy chains. HC10 reacts mostly with HLA-B and HLA-C heavy chains and some HLA-A (HLA-A10, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-A32, HLA-A33).

Immunogen: HC10 is a mouse monoclonal IgG2a antibody derived by fusion of SP2/0-Ag14 mouse myeloma cells with spleen cells from BALB/c mice immunized with HLA-B7 and -B40 heavy chains.

Clone: HC10

Isotype: IgG2a

Application Details

Application Notes: HC10 was raised against free class I heavy chains of HLA antigens to obtain antibodies that would still react with denatured class I antigens, as they occur in Western blotting, conventional light microscopical analysis of formalin-fixed, paraffin-embedded sections, and cryo-immuno-electron microscopy. HC10 indeed retains strong reactivity with free class I heavy chains in Western blots. HC10 also produces strong reactivity in immuno-electron microscopy. Its use allows the determination of tissue and subcellular distribution of class I antigen and can be used to specifically block free heavy chains (FHC), See reference 6. Optimal antibody dilutions for the different applications should be determined by titration, recommended range is 1:100 - 1:200 for flow cytometry, and for immunohistochemistry with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent, and 1:100 - 1:1000 for immunoblotting applications.

Restrictions: For Research Use only

Handling

Buffer: Each vial contains 100 μL 1 mg/mL purified monoclonal antibody in PBS containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C, or in small aliquots at -20°C.

References

Nguyen, Ramsay, Ahanfeshar-Adams, Lajoie, Schadendorf, Alain, Watson: "Mutations in the IFNγ-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment." in: Clinical cancer research : an official journal of the American Association for Cancer Research, (2021) (PubMed).

Inozume, Yaguchi, Ariyasu, Togashi, Ohnuma, Honobe, Nishikawa, Kawakami, Kawamura: "Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy." in: The Journal of investigative dermatology, Vol. 139, Issue 7, pp. 1490-1496, (2020) (PubMed).

Dijkstra, Cattaneo, Weeber, Chalabi, van de Haar, Fanchi, Slagter, van der Velden, Kaing, Kelderman, van Rooij, van Leerdam, Depla, Smit, Hartemink, de Groot, Wolkers, Sachs, Snaebjornsson, Monkhorst et al.: "Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. ..." in: Cell, Vol. 174, Issue 6, pp. 1586-1598.e12, (2019) (PubMed).

Matsutani, Shibutani, Maeda, Nagahara, Fukuoka, Nakao, Hirakawa, Ohira: "Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer." in: Cancer science, Vol. 109, Issue 4, pp. 966-979, (2018) (PubMed).

Cao, Brouwer, Jordanova, Marinkovic, van Duinen, de Waard, Ksander, Mulder, Claas, Heemskerk, Jager: "HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status." in: Investigative ophthalmology & visual science, Vol. 59, Issue 2, pp. 1005-1015, (2018) (PubMed).

Sundara, Kostine, Cleven, Bovée, Schilham, Cleton-Jansen: "Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy." in: Cancer immunology, immunotherapy : CII, Vol. 66, Issue 1, pp. 119-128, (2017) (PubMed).

Michel, Santella, Steers, Sahajpal, Downey, Thohan, Oaks: "Many de novo donor-specific antibodies recognize β2 -microglobulin-free, but not intact HLA heterodimers." in: HLA, Vol. 87, Issue 5, pp. 356-66, (2017) (PubMed).

Ravindranath, Jucaud, Ferrone: "Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers." in: Journal of immunological methods, Vol. 450, pp. 73-80, (2017) (PubMed).

Jucaud, Ravindranath, Terasaki: "Conformational Variants of the Individual HLA-I Antigens on Luminex Single Antigen Beads Used in Monitoring HLA Antibodies: Problems and Solutions." in: Transplantation, Vol. 101, Issue 4, pp. 764-777, (2017) (PubMed).

Marroquin Belaunzaran, Kleber, Schauer, Hausmann, Nicholls, Van den Broek, Payeli, Ciurea, Milling, Stenner, Shaw, Kollnberger, Bowness, Petrausch, Renner: "HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats." in: PLoS ONE, Vol. 10, Issue 6, pp. e0130811, (2016) (PubMed).

Target Details

Target: HLA Class I Heavy Chain

Background: The HLA class I gene family is composed of a group of genes whose products encode cell surface glycoproteins of MW 40-45 kDa, associated non-covalently with the beta-2-microglobulin light chain. They include the three polymorphic molecules HLA-A, -B, and -C, which are ubiquitously expressed and which are able to present intracellular peptides to cytotoxic T cells. Three additional class I genes are known, commonly referred to as non-classical or class Ib genes, all highly homologous to the other class I genes and all of which associate with beta-2-microglobulin light chain. In humans, each of the class Ib genes appears to exhibit a distinct pattern of expression in developing and adult tissues. HLA-E transcripts are distributed widely in adult tissues and have also been found in the placenta and fetal liver. In the adult, the presence of HLA-F has been shown in skin, resting T cells, and B cells, whereas its expression during development has been reported in fetal liver and at low levels in placenta and extra-placental tissues. HLA-G was originally thought to be expressed only in certain populations of placental trophoblasts, but low levels have also been found in a variety of human tissues. Recently it was shown that HLA class I expression in breast cancer cells can have a predictive value for chemotherapy response.